Funder
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Gomariz, R. P. et al. VIP-PACAP system in immunity: new insights for multitarget therapy. Ann. N. Y. Acad. Sci. 1070, 51–74 (2006).
2. González-Rey, E., Anderson, P. & Delgado, M. Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy. Ann. Rheum. Dis. 66, iii70–iii76 (2007).
3. Ganea, D., Hooper, K. M. & Kong, W. The neuropeptide VIP: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiol. (Oxf) 213, 442–452 (2015).
4. Delgado, M., Abad, C., Martínez, C., Leceta, J. & Gomariz, R. P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med 7, 563–568 (2001).
5. Abad, C. et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease. Gastroenterology 124, 961–971 (2003).
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献